[ET Net News Agency, 31 March 2021] Goldman Sachs lifted its target price for Shanghai
Fosun Pharmaceutical (02196) to HK$39 from HK$25.2 and maintained its "buy" rating.
The research house said Fosun Pharma's 2H sales of Rmb16.2bn were slightly below
Goldman's estimate, due to a slower post-covid recovery in pharma, particularly
injectables, Aodejin, GPO price cut on selected generics (e.g. quetiapine), and weaker
anti-infectives sales.
Goldman sees 2021 as a more constructive year with (1) ramp-up of biosimliars; (2) new
product launches - Yescarta and bevacizumab at NDA (new drug application); (3) rebound in
Almer laser (management guided 40% growth in 1H 2021), and (4) upside from BioNtech
covid-19 vaccines, which depends on approval timing and vaccination rollout.
Goldman revised the 2021 EPS forecast up by 3%. (KL)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02196 FOSUN PHARMA
Nominal 
11.440 -0.060 (-0.522%) Research Report
31/03/2021 17:44
{I-bank focus}Goldman lifts Fosun Pharma (02196) to HK$39
| Remark: | Real time quote last updated: 19/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |